MDGL
MDGL clinical trials: MADRIGAL PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where MADRIGAL PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 22
- Trials linked
- 21
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
MDGL on the catalyst calendar · MDGL registry changes
- Primary completion Nov 2027Sponsor estimatePhase 4NCT07848191Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisMadrigal Pharmaceuticals, Inc. · MASH - Metabolic Dysfunction-Associated SteatohepatitisRecruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 1NCT07830758Resmetirom in Patients With MASH and HFpEFMadrigal Pharmaceuticals, Inc. · MASH - Metabolic Dysfunction-Associated SteatohepatitisRecruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 2NCT07763015Study of Resmetirom in Children and Adolescents With MASHMadrigal Pharmaceuticals, Inc. · MASHRecruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2NCT07335601Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHMadrigal Pharmaceuticals, Inc. · MASH - Metabolic Dysfunction-Associated SteatohepatitisRecruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT05500222A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis...Madrigal Pharmaceuticals, Inc. · NASHActive, not recruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 3NCT03900429A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisMadrigal Pharmaceuticals, Inc. · NASH - Nonalcoholic SteatohepatitisActive, not recruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 3NCT04951219A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)...Madrigal Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver DiseaseActive, not recruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2018ActualPhase 2NCT03038022Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)Madrigal Pharmaceuticals, Inc. · Heterozygous Familial HypercholesterolemiaCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2030Sponsor estimateNo phase registeredNCT07541469Rezdiffra Pregnancy and Lactation RegistryMadrigal Pharmaceuticals, Inc. · MASH - Metabolic Dysfunction-Associated SteatohepatitisRecruitingMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 25, 2017ActualPhase 2NCT02912260Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)Madrigal Pharmaceuticals, Inc. · Non-alcoholic SteatohepatitisCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 16, 2024ActualPhase 1NCT06397872A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With...Madrigal Pharmaceuticals, Inc. · Renal ImpairmentCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 4, 2021ActualPhase 1NCT04643795Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying...Madrigal Pharmaceuticals, Inc. · Hepatic ImpairmentCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2023ActualPhase 3NCT04197479A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsMadrigal Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver DiseaseCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01367873Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsMadrigal Pharmaceuticals, Inc. · Drug SafetyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2015ActualPhase 1NCT02542969Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinMadrigal Pharmaceuticals, Inc. · HealthyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2019ActualPhase 1NCT04671069Drug Interaction Study of MGL-3196 With ClopidogrelMadrigal Pharmaceuticals, Inc. · HealthyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2018ActualPhase 1NCT04671056Drug Interaction Study of MGL-3196 With PioglitazoneMadrigal Pharmaceuticals, Inc. · HealthyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2018ActualPhase 1NCT03413124Bioavailability Study of MGL-3196 Tablets Compared to CapsulesMadrigal Pharmaceuticals, Inc. · HealthyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2017ActualPhase 1NCT03220165Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196Madrigal Pharmaceuticals, Inc. · HealthyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 1NCT02749578Drug Interaction Study of MGL-3196 With AtorvastatinMadrigal Pharmaceuticals, Inc. · HealthyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2012ActualPhase 1NCT01519531Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsMadrigal Pharmaceuticals, Inc. · Drug SafetyCompletedMDGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimateNo phase registeredNCT07860814Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom TherapyRadnet Management, Inc. · Metabolic Dysfunction-steatohepatitis (MASH)Not yet recruitingMDGLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 22 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner